Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines

Inclusion Criteria: * Healthy adult male or non-pregnant, non-lactating female, ages 18-49 (inclusive) at time of screening * Have demonstrated adequate comprehension of the protocol, by achieving a score of at least 80% correct on a short multiple-choice quiz * Individuals who fail to achieve a passing score on the initial quiz will be given the opportunity to retest after a review of protocol information * Individuals who fail the comprehension assessment for the second time will not be enrolled * Have provided written informed consent before screening * Free of clinically significant health problems, as determined by pertinent medical history and clinical examination before entry into the study * Available and able to participate for all study visits and procedures * If sexually active, known to be at least 1 year post-menopausal, or willing to use an effective method of contraception (e.g., birth control pill, diaphragm, cervical cap, intrauterine device, condom, or anatomical sterility \[in self or partner\]) from the date of screening until at least 6 months after the last vaccination * Negative hantavirus IgG antibody test result at screening (ELISA) Exclusion Criteria: * History or serologic evidence of prior infection with either HTNV or PUUV virus, or prior participation in a HTNV or PUUV virus vaccine trial * History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions * Any serologic evidence of hepatitis B or …